BY IDA JORGENSEN
-
Eli Lilly to invest USD 27bn in US production facilities
With this brand-new production dedication, the United States pharmaceutical firm intends to fulfill the need for its weight problems hits and repatriate tiny particle manufacturing…
-
Sued for almost a billion dollars: “We are disappointed by Novo Nordisk”
Huang Zhenhua, the owner of KBP Bioscience, states the reality will certainly quickly justify the biotech business. He is implicated of scams by Novo Nordisk.
-
Eli Lilly’s CEO speaks out on price negotiations and tax cuts
The Lilly chief executive officer talks about the statement that the pharmaceutical business is purchasing brand-new manufacturing centers in the United States.
-
Gubra exceeds own growth expectations in 2024
Gubra’s solution organization has actually gotten energy in 2024, and considerably greater expenses in the D&P sector are anticipated in 2025.
-
Leo Pharma reports positive results in late-stage China trial for hand eczema
It is the 6th Stage 3 test carried out by the dermatology business with delgocitinib as a therapy for persistent hand dermatitis.
-
Novo Nordisk officially launches Wegovy in Swedish pharmacies
Previously, the fat burning medicine has actually just been readily available as an identical import.
-
Eli Lilly makes notable purchase of fatty liver program
The United States drugmaker is paying a double-digit million-dollar ahead of time settlement for the program, which is presently in Stage 2 tests.
-
Almirall outperforms 2024 guidance with psoriasis cream growth beyond 50%.
Barcelona-headquartered dermatology firm Almirall has actually surpassed its very own assumptions and is seeing solid sales development for its psoriasis lotion.
-
Novo Nordisk seeks claim on Dr. Huang Zhenhua’s millions
Novo Nordisk has actually obtained a court to ice up the possessions of an affluent Singaporean physician and a biotech firm due to the fact that the Danish firm thinks it has actu…
-
Trump administration shows first signs of defending controversial drug price negotiations
The general public medication rate settlements in the United States have actually been slammed by numerous significant pharmaceutical firms– consisting of Novo Nordisk.